Jung-Yun Lee

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1412293/publications.pdf

Version: 2024-02-01

127 papers	2,227 citations	257101 24 h-index	315357 38 g-index
134 all docs	134 docs citations	134 times ranked	3268 citing authors

#	Article	IF	Citations
1	Diabetes mellitus as an independent risk factor for lung cancer: A meta-analysis of observational studies. European Journal of Cancer, 2013, 49, 2411-2423.	1.3	111
2	Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing. BMC Cancer, 2015, 15, 85.	1.1	85
3	Changes in ovarian cancer survival during the 20Âyears before the era of targeted therapy. BMC Cancer, 2018, 18, 601.	1.1	80
4	Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. Gynecologic Oncology, 2019, 154, 441-448.	0.6	74
5	4â€1BB Delineates Distinct Activation Status of Exhausted Tumorâ€Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. Hepatology, 2020, 71, 955-971.	3.6	70
6	Trends in gynecologic cancer mortality in East Asian regions. Journal of Gynecologic Oncology, 2014, 25, 174.	1.0	69
7	Outcomes of ovarian preservation in a cohort of premenopausal women with early-stage endometrial cancer: A Korean Gynecologic Oncology Group study. Gynecologic Oncology, 2013, 131, 289-293.	0.6	62
8	External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. Journal of Gynecologic Oncology, 2017, 28, e73.	1.0	58
9	Comparative Effectiveness of Abdominal versus Laparoscopic Radical Hysterectomy for Cervical Cancer in the Postdissemination Era. Cancer Research and Treatment, 2019, 51, 788-796.	1.3	57
10	Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer. American Journal of Obstetrics and Gynecology, 2021, 224, 370.e1-370.e13.	0.7	51
11	Prognosis of Cervical Cancer in the Era of Concurrent Chemoradiation from National Database in Korea: A Comparison between Squamous Cell Carcinoma and Adenocarcinoma. PLoS ONE, 2015, 10, e0144887.	1.1	51
12	Preoperative prediction model of lymph node metastasis in endometrial cancer. International Journal of Gynecological Cancer, 2010, 20, 1350-5.	1.2	39
13	Preoperative assessment of lymph node metastasis in endometrial cancer: A Korean Gynecologic Oncology Group study. Cancer, 2017, 123, 263-272.	2.0	38
14	Practice guidelines for management of cervical cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. Journal of Gynecologic Oncology, 2017, 28, e22.	1.0	38
15	Safety of Fertility-Sparing Surgery in Primary Mucinous Carcinoma of the Ovary. Cancer Research and Treatment, 2015, 47, 290-305.	1.3	37
16	Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer. Gynecologic Oncology, 2018, 151, 414-421.	0.6	36
17	Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1/2. Cancer Research and Treatment, 2018, 50, 917-925.	1.3	35
18	4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39⁺ CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. , 2020, 8, e001650.		35

#	Article	IF	Citations
19	MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis. Biochemical and Biophysical Research Communications, 2018, 497, 513-520.	1.0	34
20	Prognosis of Adenosquamous Carcinoma Compared With Adenocarcinoma in Uterine Cervical Cancer: A Systematic Review and Meta-Analysis of Observational Studies. International Journal of Gynecological Cancer, 2014, 24, 289-294.	1.2	32
21	Genetic characteristics of gastric-type mucinous carcinoma of the uterine cervix. Modern Pathology, 2021, 34, 637-646.	2.9	32
22	Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer. Gynecologic Oncology, 2018, 148, 62-67.	0.6	30
23	Two-step sentinel lymph node mapping strategy in endometrial cancer staging using fluorescent imaging: A novel sentinel lymph node tracer injection procedure. Surgical Oncology, 2018, 27, 514-519.	0.8	28
24	Identification of a Novel BRCA1 Pathogenic Mutation in Korean Patients Following Reclassification of BRCA1 and BRCA2 Variants According to the ACMG Standards and Guidelines Using Relevant Ethnic Controls. Cancer Research and Treatment, 2017, 49, 1012-1021.	1.3	28
25	Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients. Cancer Research and Treatment, 2017, 49, 408-415.	1.3	27
26	Treatment of stage IB2, IIA bulky cervical cancer: a single-institution experience of neoadjuvant chemotherapy followed by radical hysterectomy and primary radical hysterectomy. Archives of Gynecology and Obstetrics, 2011, 284, 477-482.	0.8	26
27	Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041). Gynecologic Oncology, 2019, 152, 61-67.	0.6	26
28	The Role of Omentectomy and Random Peritoneal Biopsies as Part of Comprehensive Surgical Staging in Apparent Early-Stage Epithelial Ovarian Cancer. Annals of Surgical Oncology, 2014, 21, 2762-2766.	0.7	25
29	Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study. Journal of Gynecologic Oncology, 2019, 30, e3.	1.0	25
30	Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer. BMC Cancer, 2020, 20, 204.	1.1	25
31	Upregulation of homeobox gene is correlated with poor survival outcomes in cervical cancer. Oncotarget, 2017, 8, 84396-84402.	0.8	23
32	The institutional learning curve is associated with survival outcomes of robotic radical hysterectomy for early-stage cervical cancer-a retrospective study. BMC Cancer, 2020, 20, 152.	1.1	22
33	Preoperative MRI criteria for trials on less radical surgery in Stage IB1 cervical cancer. Gynecologic Oncology, 2014, 134, 47-51.	0.6	21
34	Pretreatment neutrophil-to-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer. Obstetrics and Gynecology Science, 2018, 61, 227.	0.6	21
35	Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial. Journal of Gynecologic Oncology, 2022, 33, .	1.0	21
36	Prognostic significance of supradiaphragmatic lymph node metastasis detected by 18F-FDG PET/CT in advanced epithelial ovarian cancer. BMC Cancer, 2018, 18, 1165.	1.1	20

#	Article	IF	Citations
37	Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy. Gynecologic Oncology, 2016, 143, 622-627.	0.6	19
38	Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models. Cancer Research and Treatment, 2018, 50, 956-963.	1.3	19
39	Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer. BMC Cancer, 2018, 18, 83.	1.1	19
40	Genomic profiling of the residual disease of advanced highâ€grade serous ovarian cancer after neoadjuvant chemotherapy. International Journal of Cancer, 2020, 146, 1851-1861.	2.3	19
41	Major clinical research advances in gynecologic cancer in 2021. Journal of Gynecologic Oncology, 2022, 33, e43.	1.0	19
42	PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies. Journal of Gynecologic Oncology, 2022, 33, .	1.0	18
43	An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION. Japanese Journal of Clinical Oncology, 2019, 49, 789-792.	0.6	17
44	A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01). Journal of Gynecologic Oncology, 2021, 32, e31.	1.0	17
45	Controversies in the management of endometrial cancer: a survey of the Korean Gynecologic Oncology Group. Journal of Gynecologic Oncology, 2015, 26, 277.	1.0	16
46	The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy. Journal of Surgical Oncology, 2017, 116, 329-336.	0.8	15
47	Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer. BMC Cancer, 2020, 20, 185.	1.1	15
48	Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: Reappraisal in the era of radical surgery. Oncotarget, 2017, 8, 37807-37816.	0.8	15
49	A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D. Journal of Gynecologic Oncology, 2019, 30, e112.	1.0	15
50	Cost-effectiveness of para-aortic lymphadenectomy before chemoradiotherapy in locally advanced cervical cancer. Journal of Gynecologic Oncology, 2015, 26, 171.	1.0	14
51	Identifying a low-risk group for parametrial involvement in microscopic Stage IB1 cervical cancer using criteria from ongoing studies and a new MRI criterion. BMC Cancer, 2015, 15, 167.	1.1	14
52	Comparison of outcomes between the one-step and two-step sentinel lymph node mapping techniques in endometrial cancer. International Journal of Gynecological Cancer, 2020, 30, 318-324.	1.2	14
53	BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients. Gynecologic Oncology, 2017, 145, 137-141.	0.6	13
54	Outcomes of uterine sarcoma found incidentally after uterus-preserving surgery for presumed benign disease. BMC Cancer, 2016, 16, 675.	1.1	12

#	Article	IF	Citations
55	Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy. Journal of Korean Medical Science, 2017, 32, 2021.	1.1	12
56	Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center. Journal of Gynecologic Oncology, 2018, 29, e63.	1.0	12
57	Aberrant uterine leiomyomas with extrauterine manifestation: intravenous leiomyomatosis and benign metastasizing leiomyomas. Obstetrics and Gynecology Science, 2018, 61, 509.	0.6	12
58	Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708). BMC Cancer, 2019, 19, 341.	1.1	12
59	Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. European Journal of Cancer, 2020, 139, 59-67.	1.3	12
60	Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 165-175.	1.4	12
61	Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer. Cancers, 2022, 14, 2308.	1.7	12
62	The cost-effectiveness of selective lymphadenectomy based on a preoperative prediction model in patients with endometrial cancer: Insights from the US and Korean healthcare systems. Gynecologic Oncology, 2014, 135, 518-524.	0.6	11
63	Genetic analysis of ovarian microcystic stromal tumor. Obstetrics and Gynecology Science, 2016, 59, 157.	0.6	11
64	Prediction of perioperative complications after robotic-assisted radical hysterectomy for cervical cancer using the modified surgical Apgar score. BMC Cancer, 2018, 18, 908.	1.1	11
65	Integrating a Next Generation Sequencing Panel into Clinical Practice in Ovarian Cancer. Yonsei Medical Journal, 2019, 60, 914.	0.9	11
66	A novel algorithm for the treatment strategy for advanced epithelial ovarian cancer: consecutive imaging, frailty assessment, and diagnostic laparoscopy. BMC Cancer, 2017, 17, 481.	1.1	10
67	Pretreatment lymphocytopenia is an adverse prognostic biomarker in advancedâ€stage ovarian cancer. Cancer Medicine, 2019, 8, 564-571.	1.3	10
68	Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer. PLoS ONE, 2017, 12, e0183754.	1.1	10
69	Involved-field radiation therapy for selected cases of recurrent ovarian cancer. Journal of Gynecologic Oncology, 2019, 30, e67.	1.0	10
70	Major clinical research advances in gynecologic cancer in 2019. Journal of Gynecologic Oncology, 2020, 31, e48.	1.0	10
71	A Comparison of Adenosquamous Carcinoma and Adenocarcinoma of the Cervix after Radical Hysterectomy. Gynecologic and Obstetric Investigation, 2015, 80, 15-20.	0.7	9
72	CT-Based Fagotti Scoring System for Non-Invasive Prediction of Cytoreduction Surgery Outcome in Patients with Advanced Ovarian Cancer. Korean Journal of Radiology, 2021, 22, 1481.	1.5	9

#	Article	IF	Citations
73	How to use immune checkpoint inhibitor in ovarian cancer?. Journal of Gynecologic Oncology, 2019, 30, e105.	1.0	9
74	Treatment strategies for stage IB cervical cancer: A cost-effectiveness analysis from Korean, Canadian and US perspectives. Gynecologic Oncology, 2016, 140, 83-89.	0.6	8
75	Sentinel lymph node mapping with indocyanine green in vaginal cancer. Journal of Gynecologic Oncology, 2017, 28, e29.	1.0	8
76	Evaluation of various kinetic parameters of CA-125 in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy. PLoS ONE, 2018, 13, e0203366.	1.1	8
77	Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study. Journal of Clinical Medicine, 2019, 8, 1920.	1.0	8
78	Real-World Experience of Pembrolizumab Monotherapy in Patients with Recurrent or Persistent Cervical Cancer: A Korean Multi-Center Retrospective Study (KGOG1041). Cancers, 2020, 12, 3188.	1.7	8
79	Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study. Gynecologic Oncology, 2022, 165, 97-104.	0.6	8
80	Difference in Practice Patterns in the Management of Endometrial Cancer: A Survey of the Members of 4 East Asian Gynecologic Oncology Groups. International Journal of Gynecological Cancer, 2017, 27, 1888-1894.	1.2	7
81	Surgical technique for single-port laparoscopy in huge ovarian tumors: SW Kim's technique and comparison to laparotomy. Obstetrics and Gynecology Science, 2017, 60, 178.	0.6	7
82	Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy. Journal of Clinical Medicine, 2020, 9, 1235.	1.0	7
83	Comparison of single-port laparoscopy and laparotomy in early ovarian cancer surgical staging. Obstetrics and Gynecology Science, 2021, 64, 90-98.	0.6	7
84	Dysregulated expression of homeobox family genes may influence survival outcomes of patients with epithelial ovarian cancer: analysis of data from The Cancer Genome Atlas. Oncotarget, 2017, 8, 70579-70585.	0.8	7
85	Recommendations for gynecologic cancer care during the COVID-19 pandemic. Journal of Gynecologic Oncology, 2020, 31, e69.	1.0	7
86	Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response. Cancer Research, 2022, 82, 142-154.	0.4	7
87	4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39 CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. , 2020, 8, .		7
88	Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience. Yonsei Medical Journal, 2018, 59, 930.	0.9	6
89	Effects of Korean Red Ginseng (Panax ginseng C.A. Meyer) on Menopausal Symptoms in Premenopausal Women After Gynecologic Cancer Surgery: A Double-Blind, Randomized Controlled Trial. Journal of Alternative and Complementary Medicine, 2021, 27, 66-72.	2.1	6
90	A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer. Yonsei Medical Journal, 2020, 61, 284.	0.9	6

#	Article	IF	Citations
91	A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial. Journal of Gynecologic Oncology, 2022, 33, .	1.0	6
92	Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea. Gynecologic Oncology, 2022, 165, 369-375.	0.6	6
93	Detecting Asymptomatic Recurrence in Early-Stage Endometrial Cancer: The Value of Vaginal Cytology, Imaging Studies, and CA-125. International Journal of Gynecological Cancer, 2016, 26, 1434-1439.	1.2	5
94	Distinct Clinical Courses of Epithelial Ovarian Cancer with Mutations in BRCA1 5â€™ and 3â€™ Exons. Anticancer Research, 2018, 38, 6947-6953.	0.5	5
95	Periumbilical infiltration of lidocaine with epinephrine for postoperative pain reduction in single-port laparoscopic adnexal surgery. Journal of Obstetrics and Gynaecology, 2018, 38, 1135-1139.	0.4	5
96	AdvanTIG-202: A phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer.. Journal of Clinical Oncology, 2021, 39, TPS5595-TPS5595.	0.8	5
97	ARL6IP5 reduces cisplatin-resistance by suppressing DNA repair and promoting apoptosis pathways in ovarian carcinoma. Cell Death and Disease, 2022, 13, 239.	2.7	5
98	Treatment Preferences for Routine Lymphadenectomy Versus No Lymphadenectomy in Early-Stage Endometrial Cancer. Annals of Surgical Oncology, 2017, 24, 1336-1342.	0.7	4
99	Transcatheter Arterial Embolization for Severe Secondary Hemorrhage after Hysterectomy. Journal of Minimally Invasive Gynecology, 2018, 25, 180-185.	0.3	4
100	Patterns of initially overlooked recurrence of peritoneal lesions in patients with advanced ovarian cancer on postoperative multi-detector row CT. Acta Radiologica, 2019, 60, 1713-1720.	0.5	4
101	Effectiveness of adjuvant treatment for morcellated, International Federation of Gynecology and Obstetrics stage I uterine leiomyosarcoma: A Korean multicenter study. Journal of Obstetrics and Gynaecology Research, 2019, 46, 337-346.	0.6	4
102	Time for enhancing government-led primary prevention of cervical cancer. Journal of Gynecologic Oncology, 2021, 32, e12.	1.0	4
103	Role of preoperative magnetic resonance imaging and histological assessment in identifying patients with a low risk of endometrial cancer: a Korean Gynecologic Oncology Group ancillary study. Oncotarget, 2017, 8, 106009-106016.	0.8	4
104	An Alternative Triage Strategy Based on Preoperative MRI for Avoiding Trimodality Therapy in Stage IB Cervical Cancer. Cancer Research and Treatment, 2016, 48, 259-265.	1.3	4
105	Early Assessment of Response to Neoadjuvant Chemotherapy with ¹⁸F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer. Cancer Research and Treatment, 2020, 52, 1211-1218.	1.3	4
106	Indocyanine green fluorescent image-guided inguinal sentinel lymph node biopsy in vulvar cancer. Obstetrics and Gynecology Science, 2022, 65, 223-225.	0.6	4
107	Surgical manual of the Korean Gynecologic Oncology Group: ovarian, tubal, and peritoneal cancers. Journal of Gynecologic Oncology, 2017, 28, e6.	1.0	3
108	Association between PD-L1 expression and 18F-FDG uptake in ovarian cancer. Annals of Nuclear Medicine, 2021, 35, 415-420.	1.2	3

#	Article	IF	Citations
109	Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee. Gynecologic Oncology, 2021, 161, 502-507.	0.6	3
110	Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer. Journal of Gynecologic Oncology, 2020, 31, e23.	1.0	3
111	Cancer Patient Tissueoid with Selfâ€Homing Nanoâ€Targeting of Metabolic Inhibitor. Advanced Science, 2021, 8, 2102640.	5.6	3
112	Effect of bupivacaine versus lidocaine local anesthesia on postoperative pain reduction in single-port access laparoscopic adnexal surgery using propensity score matching. Obstetrics and Gynecology Science, 2020, 63, 363-369.	0.6	3
113	Prognostic value of complete metabolic response on 18F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer. Journal of Gynecologic Oncology, 2022, 33, .	1.0	3
114	Management of cervical cancer patients with isolated para-aortic lymph node metastases. Journal of Gynecologic Oncology, 2013, 24, 382.	1.0	2
115	Knowledge of HPV and Surgery among Women Who Underwent Cervical Conization: A Korean Multi-Center Study. Yonsei Medical Journal, 2016, 57, 1222.	0.9	2
116	Diagnostic Value of 18F-FDG PET/CT and MRI in the Preoperative Evaluation of Uterine Carcinosarcoma. Nuclear Medicine and Molecular Imaging, 2018, 52, 445-452.	0.6	2
117	Survival outcomes of single-port access laparoscopic radical hysterectomy for early-stage cervical cancer. Surgical Oncology, 2020, 34, 140-145.	0.8	2
118			

#	Article	IF	Citations
127	A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.. Journal of Clinical Oncology, 2022, 40, TPS5610-TPS5610.	0.8	0